NV-ARMIS
Black Hat – Armis, the asset intelligence cybersecurity company, announced today that it has surpassed $200m in annual recurring revenue (ARR), doubling its ARR in less than 18 months and making it one of just a few companies that have achieved this rapid scale, not just in the cybersecurity market, but of any SaaS company worldwide.
Armis’ explosive growth has been driven by its award-winning AI-powered cyber exposure management platform, Armis Centrix™, which has been adopted by the world’s leading organizations, including 35 of the top Fortune 100 companies. Customers like United Airlines, the U.S Postal Service, Ryanair, Mondelez, Reckitt and Flex trust Armis to help them secure their most critical environments. Great demand from national, state, local and Federal entities has led to increased deployment of Armis’ solutions globally. Armis also saw continued momentum across North America, EMEA and APJ which has led Armis to double its ARR in less than 18 months.
“This significant milestone reflects not just our huge financial growth in the last year but shows the unwavering trust that Fortune 100, 200, and 500 companies, large private organizations and healthcare systems, and governments place in us to safeguard their mission critical assets & infrastructure,” said Yevgeny Dibrov, Co-Founder and CEO at Armis. “Our commitment to empowering businesses with robust asset intelligence and security, proactive defense strategies and full risk management has never been stronger. As we continue to expand our impact across industries, this milestone fuels our mission to ensure that every organization can operate confidently in the face of evolving threats.”
Armis’ mission is to protect organizations' entire attack surface by managing cyber risk exposure in real time. Its cloud-based platform Armis Centrix™ and its suite of solutions proactively mitigate all cyber asset risks by identifying every asset, from the ground to the cloud, remediating vulnerabilities and blocking threats to give organizations peace of mind that all critical assets are protected.
Demand for Armis’ award-winning platform Armis Centrix™ continues at a rapid pace. Armis has expanded its capabilities & offerings, with the back to back acquisitions earlier this year of CTCI and Silk Security. Armis Centrix™ product suites now include deeper vulnerability mitigation, prioritization, remediation, risk management and threat intelligence. It has developed a world-class partner first approach and seen expansion with some key partnerships over the last few years such as Accenture, Blackwood, Booz Allen Hamilton, CDI, Fortinet, GuidePoint Security, HCl, KPMG, Nomios, Optiv, Presidio, PWC, Softcat, Source IT Technologies, Telia Cygate, WWT and the AWS and Google Marketplaces.
“Over the past year we have been laser focused on efficient growth, expansion of customer engagement, adoption of our platform Armis Centrix™️, its 5 product suites, and have focused more on expanding our channel partner engagement,” said Jonathan Carr, Chief Financial Officer of Armis. “With our recent acquisitions and expanded capabilities, we continue to see high demand for our platform, its products and are growing well in excess of top public company benchmarks, in addition to our own industry peers.”
“Armis is an integral part of Main Line Health’s cybersecurity program, providing unparalleled visibility into every asset and device within our environment,” said Aaron Weismann, Chief Information Security Officer at Main Line Health. “As a hospital system dedicated to delivering safe, high-quality, equitable and affordable care to treat and cure disease, Armis allows us to focus on what truly matters.”
Industry analysts have recognized Armis’ broad platform offering with Frost & Sullivan awarding Armis two Best Practices awards - Customer Value Leadership for OT Cybersecurity and Technology Innovation Leadership for Global Healthcare Cybersecurity.
Additional industry analyst firm recognition:
The Forrester Wave™: Operational Technology Security Solutions, Q2 2024, “Armis is ideally suited for organizations needing to manage a diverse and sprawling IoT and OT environment.”
Manuel Alborez, Frost & Sullivan Best Practices Research Analyst, “The Armis Centrix™ platform’s overarching distinction is that, through a single pane of glass, it provides a real-time, contextual view of the environment and security posture, monitoring and managing all assets affecting patient care, including IT, OT, IoT, medical devices, enterprise assets, and cloud infrastructure. In addition to this robust visibility, Armis offers cutting-edge threat intelligence and forensic monitoring capabilities.”
Danielle VanZandt, Frost & Sullivan Industry Manager – Commercial & Public Security, “In the face of a sprawling IT, OT, and IoT ecosystem, Armis provides its customers with the centralized management needed to protect their businesses. As organizations shift away from network-centric security, Armis acknowledges the potential vulnerability of any asset type. This enables them to guide security teams in proactive mitigation efforts, safeguarding the robustness of essential business processes across various sectors.”
Chris Ray, GigaOm Analyst, “Armis is a formidable player in the ASM landscape, focusing on asset discovery and management. At its core, the platform utilizes a dual-method approach for asset discovery: integration-based discovery for known assets and deep packet inspection (DPI) of network traffic to unearth everything else.”
Additional analyst recognition and awards have been received in the last 12 months and are a testament to Armis’ award-winning Armis Centrix™ platform and approach to customer success:
- Armis is a Leader in two 2024 GigaOm Radar reports: “GigaOm Radar for Attack Surface Management” and “GigaOm Radar for OT Security.”
- Armis won the “2024 Frost & Sullivan Technology Innovation Leadership Award for Global Healthcare Cybersecurity.”
- Armis won the “2024 Frost & Sullivan Customer Value Leadership Award for Operational Technology Cybersecurity.”
- KLAS Research recognized Armis as a Healthcare IoT Security Top Performer in the 2024 Best in KLAS Software & Services.
- Armis is a Leader in the “Frost Radar for Operational Technology Cybersecurity Solutions, 2023.”
- Armis is named a Representative Vendor in three 2023 Gartner Market Guides: “Market Guide for Vulnerability Assessment,” “Market Guide for CPS Protection Platforms,” and “Market Guide for Medical Device Security.”
Recent awards in the last year are as follows:
- Inc.’s 2024 Best Workplaces List
- 2024 Cybersecurity Excellence Awards
- Cyber Defense Magazine's 2024 Global InfoSec Awards
- 2024 Cloud Security Awards
- CRN Security 100 2024
- CRN Internet of Things 50 2024
- CRN Partner Program Guide 2024
- Fast Company’s Most Innovative Companies 2023
- EY Entrepreneur of The Year 2023 Bay Area Winner; Armis CEO and Co-Founder, Yevgeny Dibrov
- 2023 ‘ASTORS’ Awards - Platinum Award Winner
- 2023 Inc. 5000
- Deloitte Technology Fast 500 2023
About Armis
Armis, the asset intelligence cybersecurity company, protects the entire attack surface and manages the organization’s cyber risk exposure in real time. In a rapidly evolving, perimeter-less world Armis ensures that organizations continuously see, protect and manage all critical assets – from the ground to the cloud. Armis secures Fortune 100, 200 and 500 companies as well as national governments, state and local entities to help keep critical infrastructure, economies and society stay safe and secure 24/7. Armis is a privately held company headquartered in California.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240806677978/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
